Clinical Director, Cell and Gene Therapy Program, Mass General

Matthew Frigault, MD, MS

CART-ddBCMA, an investigational autologous chimeric antigen receptor (CAR) T-cell therapy which uses a novel synthetic binding domain referred to as a D-Domain to target B-cell maturation antigen (BCMA), has continued to demonstrate clinical activity and a manageable safety profile in a phase 1 study (NCT04155749) in patients with relapsed/refractory (r/r) multiple myeloma (MM), according to updated data presented at the 

64th Annual American Society of Hematology (ASH) Meeting

, held December 10-13, 2022, in New Orleans, Louisiana.

 sat down with primary investigator Matthew Frigault, MD, MS, of Mass General, to learn more about the 

 and where the novel therapy may fit into the treatment landscape. 

Frigault M, Rosenblatt JR, Dhakal, B, et al. Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma. Presented at: 2022 ASH Annual Meeting. December 10-13, 2022; New Orleans, LA. Abstract 33132.

Videos

The study's primary investigator shared his thoughts on where CART-ddBCMA could fit within the treatment landscape. 

Matthew Frigault, MD, MS

Articles

Matthew Frigault, MD, MS, on CART-ddBCMA's Potential in Multiple Myeloma